title: [Treatment of advanced maxillary sinus squamous carcinoma: an analysis of 92 cases].
abstract: OBJECTIVE
  There is no satisfactory treatment for advanced maxillary sinus squamous carcinoma. The treatment strategy is controversial. This study aimed to explore a rational treatment for advanced maxillary sinus squamous carcinoma.
  
  
  METHODS
  Clinical data of 92 patients with stage T3-T4 maxillary sinus squamous cell carcinoma, treated in Cancer Center of Sun Yat-sen University from Jan.1978 to Dec.2001, were reviewed. Of the 92 patients, 21 received radiotherapy alone, 8 received surgery alone, 63 received multimodality therapy (51 received surgery combined with radiotherapy, and 12 received chemoradiotherapy).
  
  
  RESULTS
  The 3-and 5-year survival rates were significantly lower in radiotherapy group and surgery group than in multimodality therapy group (19.0% and 25.0% vs. 46.0%, P<0.05; 9.5% and 12.5% vs. 33.3%, P<0.05). In multimodality therapy group, the 3-and 5-year survival rates were 33.3% and 23.8% for the patients who received radiotherapy followed by surgery, 52.9% and 47.1% for the patients who received surgery follow by radiotherapy, 53.8% and 30.8% for the patients who received pre-and postoperative radiotherapy, and 50.0% and 33.3% for the patients who received chemoradiotherapy. There were no significant differences in survival rate between these four subgroups (P>0.05).
  
  
  CONCLUSIONS
  The efficacy of multimodality therapy is better than that of single therapy strategy for advanced maxillary sinus squamous carcinoma. The best treatment pattern for advanced maxillary sinus squamous carcinoma needs further research.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.
authors.forename: Yao-Rong
authors.initials: YR
authors.lastname: Su
authors.forename: Guo-Hao
authors.initials: GH
authors.lastname: Wu
authors.forename: Zong-Yuan
authors.initials: ZY
authors.lastname: Zeng
authors.forename: Zhu-Ming
authors.initials: ZM
authors.lastname: Guo
authors.forename: Wen-Kuan
authors.initials: WK
authors.lastname: Chen
authors.forename: Mao-Wen
authors.initials: MW
authors.lastname: Wei
authors.forename: Yan-Feng
authors.initials: YF
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008443:Maxillary Sinus / Q000601:surgery*; D008444:Maxillary Sinus Neoplasms / Q000473:pathology / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D011882:Radiotherapy, High-Energy; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
chemical_list: D001761:Bleomycin; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate